Why is Gilead Sciences acquiring Arcellx?

Gilead Sciences is acquiring Arcellx to significantly expand its cancer drug pipeline and integrate Arcellx's novel immunotherapies for cancer and other incurable diseases.

What is the value of the Arcellx acquisition by Gilead?

The acquisition of Arcellx by Gilead Sciences has an equity value of up to $7.8 billion.

What kind of treatments does Arcellx develop?

Arcellx Inc. develops a new class of immunotherapies aimed at treating patients with cancer and other incurable diseases.

Home / Business and Economy / Gilead Buys Arcellx For $7.8B Cancer Push

Gilead Buys Arcellx For $7.8B Cancer Push

23 Feb

•

Summary

Gilead acquired Arcellx for up to $7.8 billion.
The deal aims to strengthen Gilead's cancer drug pipeline.
Arcellx develops new immunotherapies for incurable diseases.

Gilead Buys Arcellx For $7.8B Cancer Push

Gilead Sciences Inc. has agreed to acquire Arcellx Inc. for an equity value potentially reaching $7.8 billion. This acquisition is a key move to expand Gilead's presence in the cancer treatment sector.

The deal involves Gilead paying $115 per share in cash, with an additional $5 per share contingent on future sales performance. Arcellx is recognized for its development of novel immunotherapies targeting cancer and other intractable conditions.

This strategic acquisition is expected to strengthen Gilead's existing capabilities, particularly in oncology. The transaction is anticipated to conclude by the second quarter of 2026.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.